Oncolytics Biotech Inc. has been granted patent for extracting virus from cell culture

08-Mar-2007

Oncolytics Biotech Inc. has been granted U.S. Patent 7,186,542 entitled "Method of Extracting Virus from Cell Culture." The claims describe a method of producing infectious reovirus that allows for the removal of cell debris by filtration and concentration of the filtrate.

"This patent expands on similar manufacturing patents secured by the Company," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

SEQUENOM Secures Rights to Key Non-Invasive Prenatal Diagnostic Intellectual Property

Evogene and Zeraim Gedera Salt Tolerant Tomato Collaboration Advances to Second Phase

Heptares granted patents covering stabilised receptor technology in Europe and Japan - Key patent grants protect Heptares’ leading position in GPCR-targeted drug design and discovery

Pevion’s therapeutic Candida vaccine shows robust systemic and mucosal immunogenicity

Covestro and Genomatica produce important chemical raw material using biotechnology - Breakthrough for HMDA, widely-used ingredient, paves the way for more sustainable coatings, apparel, adhesives and plastics

Covestro and Genomatica produce important chemical raw material using biotechnology - Breakthrough for HMDA, widely-used ingredient, paves the way for more sustainable coatings, apparel, adhesives and plastics

Amarin corporation Appoints Colin W. Stewart as President and Chief Executive Officer

Discovery of quantum vibrations in 'microtubules' corroborates theory of consciousness

Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million - “Over the past decade, M Ventures has established itself globally as a leading partner to the biotech and tech venture ecosystems”

Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million - “Over the past decade, M Ventures has established itself globally as a leading partner to the biotech and tech venture ecosystems”

Genmab and Seattle Genetics Enter Into Antibody-Drug Conjugate Research Collaboration

A sprinkle of platinum nanoparticles onto graphene makes brain probes more sensitive

A sprinkle of platinum nanoparticles onto graphene makes brain probes more sensitive

Merck and Washington University working on diagnostics and treatment of malnutrition - Genome editing to be used in intestinal bacteria research

Biophage Pharma announces sale of Immunotox Labs Division to Validapro BioSciences Inc